Immunotherapy · 2023 · 12 citations · 25 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyMonoclonal AntibodiesAntibody CharacterizationAntitumor T Cell ResponsesBispecific AntibodiesCancer ImmunotherapyT Cell Responses To TumorsTherapeutic Monoclonal AntibodiesAntitumor Immune ActivationCancer Cell LysisCd19-directed Bispecific AntibodiesCd28 SignalingCd3-directed Bispecific AntibodiesCell LysisSingle-chain Variable FragmentsTumor-specific T Cell Activation
Aim: A novel CD19xCD3xCD28 trispecific antibody with a tandem single-chain variable fragments (scFv) structure was developed for the treatment of B-cell malignancies. Methods: The trispecific antibody in inducing tumor-directed T-cell activation and cytotoxicity was evaluated in vitro and in vivo and compared with its bispecific counterpart BiTE-CD19xCD3 lacking a CD28-targeting domain. Results: The trispecific antibody with a co-stimulatory domain exhibited augmented T-cell activation and memory T-cell differentiation capability and it induced faster tumor cell lysis than the bispecific antibody. RNAseq analysis revealed that the trispecific antibody modulates CD3/TCR complex-derived signal and upregulates antiapoptotic factors to influence the survival of T cells. Conclusion: By CD3/CD28 co-engagement, the trispecific antibody demonstrated its advantages in T-cell immunity and potential use as a more powerful and long-lasting T-cell engager.
25
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Lawrence Boise, Andy J. Minn, Patricia J. Noel et al. · Immunity · 1995 · 1.2K citations · Full text
Sun Young Rha, Timothy Larson, Mark D. Kochenderfer · The Lancet Oncology · 2023 · 622 citations · Full text
Medicine, Oncology, Pharmacology +13
Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation
Sònia Guedan, Avery D. Posey, Carolyn E. Shaw et al. · JCI Insight · 2018 · 580 citations · Full text